Get the Stockscreener App
9.38
1.96%
0.18
After Hours:
9.37
-0.01
-0.11%
Exagen Inc stock is traded at $9.38, with a volume of 117.14K.
It is up +1.96% in the last 24 hours and up +34.19% over the past month.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
See More
Previous Close:
$9.20
Open:
$9.26
24h Volume:
117.14K
Relative Volume:
0.38
Market Cap:
$206.39M
Revenue:
$52.55M
Net Income/Loss:
$-23.69M
P/E Ratio:
-9.9787
EPS:
-0.94
Net Cash Flow:
$-15.29M
1W Performance:
+5.99%
1M Performance:
+34.19%
6M Performance:
+95.82%
1Y Performance:
+177.51%
1-Day Range:
$9.09
$9.40
1-Week Range:
$8.48
$9.40
52-Week Range:
$2.38
$9.40
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
9.38 | 196.05M | 52.55M | -23.69M | -15.29M | -0.94 |
|
TMO
Thermo Fisher Scientific Inc
|
462.39 | 169.53B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
199.76 | 139.75B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
652.11 | 49.94B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
114.13 | 32.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
180.09 | 30.17B | 15.50B | 1.33B | 2.16B | 7.34 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-23-25 | Initiated | Craig Hallum | Buy |
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
What recovery options are there for Exagen Inc.Stock Forecast Tools for Retail Traders - Newser
Exagen Inc. Recovery Gathers Momentum on Chart SignalsAI Based High Gain Watchlist Scanner Shared - beatles.ru
What candlestick patterns are forming on Exagen Inc.Market Timing Strategy with Technical Filters - Newser
What makes Exagen Inc. stock price move sharplyLong-Term Growth Trend Summary With Confidence - Newser
How to use a screener to detect Exagen Inc. breakoutsFree Profit Target Stock Opportunity Monitor - Newser
Exagen Inc. stock outlook for YEARFree Price Action Based Buy Opportunity List - Newser
Comparing Exagen Inc. in custom built stock radarsCapital Growth Summary Over Five Years - Newser
Is Exagen Inc. reversing from oversold territorySafe Entry Zone Based on Chart Analysis - Newser
What risks could impact Exagen Inc. stock performancePattern Breakout Entry Stock Forecast in Focus - metal.it
What’s next for Exagen Inc. stock priceReversal Signal Prediction Based on Volume - Newser
Building trade automation scripts for Exagen Inc.Free ROI Boosting Trade Opportunity Calendar - Newser
Applying big data sentiment scoring on Exagen Inc.Weekly Entry Signal Based Forecast Tool - Newser
Exagen Inc. to Participate in Third Quarter Investor Conferences - The Manila Times
Exagen Doubles Down on Investor Outreach: Set for Major Healthcare Conference Circuit - Stock Titan
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too - simplywall.st
What drives Exagen Inc. stock priceFree Stock Market Beginners Guide - Jammu Links News
What are the latest earnings results for Exagen Inc.Discover breakthrough trading strategies - Jammu Links News
Is Exagen Inc. a good long term investmentMaximize your gains with expert trading tips - Jammu Links News
What are Exagen Inc. company’s key revenue driversBreakthrough financial growth - Jammu Links News
What are analysts’ price targets for Exagen Inc. in the next 12 monthsSuperior returns - Jammu Links News
What is the risk reward ratio of investing in Exagen Inc. stockBreakthrough profit margins - Jammu Links News
What catalysts could drive Exagen Inc. stock higher in 2025Build wealth steadily with smart stock selection - Jammu Links News
Is Exagen Inc. a growth stock or a value stockInvest smarter with advanced market data - Jammu Links News
Is Exagen Inc. stock overvalued or undervaluedMaximize gains with proven stock analysis - Jammu Links News
Is it the right time to buy Exagen Inc. stockRemarkably fast returns - Jammu Links News
What is the dividend policy of Exagen Inc. stockUnmatched profit potential - Jammu Links News
Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline - MSN
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Exagen Inc. Reports Record Revenue Amidst Growth Challenges - The Globe and Mail
What markets is Exagen Inc. expanding into Is LILA stock a good long term investment optionExpert Picks Data Feed For Consistent Profits - Jammu Links News
Personalized Medicine Market Future Business Opportunities - openPR.com
Exagen Analyst Ratings: Bullish Sentiment Dominates - AInvest
Exagen's Q2 Growth Validates Buy Rating, Analyst Says - AInvest
Exagen price target raised to $11 from $8 at Canaccord - TipRanks
Exagen price target raised to $10 from $7 at Cantor Fitzgerald - TipRanks
Canaccord Genuity Sticks to Its Buy Rating for Exagen (XGN) - The Globe and Mail
Exagen stock price target raised to $10 from $7 at Cantor Fitzgerald - Investing.com Nigeria
Exagen stock price target raised to $10 from $7 at Cantor Fitzgerald By Investing.com - Investing.com South Africa
KeyBanc upgrades Exagen on improved revenue visibility - TipRanks
Visual analytics tools that track Exagen Inc. performanceLow Risk Stock Selection Strategy Guide - Newser
KeyBanc upgrades Exagen stock to Overweight on improved pricing and growth - Investing.com Nigeria
Chart based analysis of Exagen Inc. trendsTop Stock Picks with Forecast Accuracy - Newser
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exagen Inc Stock (XGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NMSIC Co-Investment Fund, L.P. | 10% Owner |
Nov 20 '24 |
Sale |
3.30 |
200,000 |
660,040 |
2,108,958 |
| Black Jeffrey G. | Chief Financial Officer |
Nov 15 '24 |
Buy |
2.98 |
22,298 |
66,448 |
274,492 |
| ABALLI JOHN | President and CEO |
Nov 14 '24 |
Buy |
2.81 |
24,305 |
68,297 |
689,799 |
0.68%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):